title: Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned.
abstract: OBJECTIVE
  Peritoneal recurrence of ovarian cancer is frequent after primary surgery and chemotherapy and has poor long-term survival. De novo cytoreductive surgery is crucial with the potential to improve prognosis, especially when combined with hyperthermic intraperitoneal chemotherapy (HIPEC).
  
  
  METHODS
  The sampled data of 40 consecutive patients were retrospectively analyzed. Thirty-one patients were treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy.
  
  
  RESULTS
  No patient was lost in the perioperative period, and the combined procedure was performed with acceptable morbidity. Colon-preserving cytoreductive surgery was associated with reduced morbidity.
  
  
  CONCLUSIONS
  Patients suffering from peritoneal recurrence of ovarian cancer should be considered for radical reoperation with HIPEC in a center with expertise in multimodal therapeutic options. Organ-preserving cytoreductive surgery allows complete cytoreduction with the goal of decreasing morbidity.
authors.affiliation: Department of General, Visceral and Transplant Surgery, Comprehensive Cancer Center, University of Tübingen, Hoppe-Seyler-Strasse 3, 72076 Tübingen, Germany. ingmar.koenigsrainer@med.uni-tuebingen.de
authors.forename: Ingmar
authors.initials: I
authors.lastname: Königsrainer
authors.forename: Stefan
authors.initials: S
authors.lastname: Beckert
authors.forename: Sven
authors.initials: S
authors.lastname: Becker
authors.forename: Derek
authors.initials: D
authors.lastname: Zieker
authors.forename: Tanja
authors.initials: T
authors.lastname: Fehm
authors.forename: Eva-Maria
authors.initials: EM
authors.lastname: Grischke
authors.forename: Olivia
authors.initials: O
authors.lastname: Lauk
authors.forename: Jörg
authors.initials: J
authors.lastname: Glatzle
authors.forename: Björn
authors.initials: B
authors.lastname: Brücher
authors.forename: Diethelm
authors.initials: D
authors.lastname: Wallwiener
authors.forename: Alfred
authors.initials: A
authors.lastname: Königsrainer
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D007263:Infusions, Parenteral; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D010052:Ovariectomy / Q000379:methods*; D010534:Peritoneal Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment; D018709:Statistics, Nonparametric; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents